PTC Therapeutics

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

 
Press Releases
  Date Title and Summary View
Dec 19, 2014
SOUTH PLAINFIELD, N.J., Dec. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan-drug designation (ODD) to Translarna™ (ataluren) for the treatment of patients with Mucopolysaccharidosis I (MPS I). MPS I...
Dec 17, 2014
SOUTH PLAINFIELD, N.J., Dec. 17, 2014 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2014 it approved non-statutory stock options to purchase an aggregate of 46,750 shares of its common stock to ten new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our ne...
Dec 3, 2014
SOUTH PLAINFIELD, N.J., Dec. 3, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) is now commercially available to patients in Germany, the first country to launch in the European Union (EU), with first shipments expected to begin this week.   "The launch of Translarna in Germany ma...
Nov 21, 2014
SOUTH PLAINFIELD, N.J., Nov. 21, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that the 2014 Legend of Technology Award for Vision, Innovation, and Leadership has been awarded to Stuart W. Peltz, Ph.D., Chief Executive Officer. This award recognizes an individual who has had a significant impact on the technology i...
Nov 19, 2014
SOUTH PLAINFIELD, N.J., Nov. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a Phase 1b/2a study in adult and pediatric patients. The placebo-controlled, randomized, multiple-dose study will enroll ...
Nov 17, 2014
SOUTH PLAINFIELD, N.J., Nov. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 14, 2014 it approved non-statutory stock options to purchase an aggregate of 92,000 shares of its common stock to fifteen new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of...
Nov 17, 2014
SOUTH PLAINFIELD, N.J., Nov. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Tuyen Ong, M.D., MRCOphth, MBA, as Senior Vice President, Head of Clinical Development and Translational Research. Dr. Ong will be responsible for Clinical Development and Operations across all of PTC's therapeutic areas in...
Nov 14, 2014
SOUTH PLAINFIELD, N.J., Nov. 14, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) received the Outstanding Innovation Award at The 2014 Rare & Orphan Advocacy & Research Awards for Translarna™, the first treatment approved in the European Union for Duchenne muscular dystrophy. The Rare & Orphan Advocacy & Research (ROAR) Awar...
Nov 13, 2014
SOUTH PLAINFIELD, N.J., Nov. 13, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it will hold its 2nd Annual Science Day on Monday, November 24, 2014 from 8:00 a.m. to 12:00 p.m. ET at the Le Parker Meridien in New York City. Members of PTC's senior management and research teams will provide a corporate update and in...
Nov 6, 2014
SOUTH PLAINFIELD, N.J., Nov. 6, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the third quarter ended September 30, 2014. "During the quarter we continued to make significant progress during this transformative time for PTC. For the first time in the company'...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue